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» BACKGROUND
Stable dose cannabinoid medicine (Sativex®, THC+CBD) can provide sustained efficacy in the treatment of refractory painful diabetic neuropathy or 
other peripheral neuropathic pain associated with allodynia.
Ratcliffe S1, Serpell MG2, Hoggart B3, Simpson K4
1MAC UK Neuroscience Ltd., Blackpool, UK; 2Gartnavel General Hospital, Glasgow, UK; 3Solihull Hospital, Solihull, UK; 4Seacroft Hospital, Leeds, UK.
» CONCLUSION
Neuropathic Pain (NP) poses a major challenge:  
• Most common long-term complication of diabetes mellitus
• Leads to great morbidity and mortality
• Results in a huge economic burden for diabetes care
• Can be a disabling and painful symptom
• Existing treatments afford only partial relief and have 
unpleasant side-effects
• Sativex remained well tolerated and beneficial for the majority of subjects with peripheral neuropathic pain secondary to diabetes or associated with allodynia over nine months.
• Maintenance in pain relief was achieved without an increase in dose of Sativex.
• The study raised no new safety concerns for Sativex. 
2. Baseline Subject Characteristics
3. Mean NRS Pain Scores 7. Safety
• 295 subjects reported at least 1 treatment-emergent AE; 224 subjects (59%) were related
• 88 subjects (23%) reported at least 1 AE leading to permanent cessation of study medication.
• Severe AEs affected 87 subjects (23%).
• 40 subjects (11%) reported at least one SAE; 4 subjects (1%) were related:
• 2 subjects experienced amnesia, 1 resolved following discontinuation of Sativex and 1 was 
still ongoing at last visit; 1 subject experienced paranoia which resolved following 
discontinuation of Sativex; 1 suicide attempt occurred 26 days after last dose.
• 2 fatal non-related AEs occurred.
4. Responders at the 30% and 50% Level of Improvement 
6. Secondary Endpoints
1. Disposition of Subjects
There was an improvement over the initial weeks of treatment and subsequent 
maintenance of benefit.
Common adverse events (occurring in 5% or more subjects)
No. of Subjects (%) 
(n=380)
Gender Male 200 (53%)
Female 180 (47%)
Ethnic Origin White/Caucasian 374 (98%)
Other 6 (2%)
Previous Cannabis Use (at any time, prior to parent RCTs) 38 (10%)
Mean (SD)
Age (years) 57.8 (12.03)
BMI (kg/m2) 29.9 (6.76)
Duration of Any Underlying Condition Causing PNP (years) 9.63 (8.45)
Duration of PNP (years) 5.35 (5.30)
After 9 months of open label Sativex treatment, 141 (61%) completing subjects reported pain 
scores that were improved by ≥30% from the parent RCT baseline 12 months earlier
System Organ Class
Preferred Term
All-Causality 
Number (Percentage) of Subjects                                 
Treatment-Related
Number (Percentage) of Subjects
Total subjects with at least one AE 295 (78%) 224 (59%)
Nervous System Disorders
Dizziness
Dysgeusia
Somnolence
Headache
168 (44%)
79 (21%)
29 (8%)
28 (7%)
23 (6%)
140 (37%)
74 (19%)
28 (&%)
27 (7%)
11 (3%)
Gastrointestinal Disorders
Nausea
Dry Mouth
Vomiting
135 (36%)
42 (11%)
30 (8%)
25 (7%)
97 (26%)
35 (9%)
29 (8%)
11 (3%)
General Disorders and Administration Site 
Conditions
Fatigue
Feeling Drunk
92 (24%)
31 (8%)
21 (6%)
69 (18%)
27 (7%)
21 (6%)
Psychiatric Disorders
Disorientation
79 (21%)
19 (5%)
55 (14%)
18 (5%)
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» METHODS
Study Design:
• 38-week open label, follow-on study
Study Objectives:
• To evaluate maintenance of effect and development of tolerance through exposure to, and safety of open label Sativex therapy in subjects with peripheral neuropathic pain (PNP)
Study Population:
• 380 subjects who had participated in one of two 3-month (GWCL0305 and GWCL0405), double blind, randomised controlled clinical trials (parent RCT) designed to investigate the role of 
Sativex in the treatment of PNP secondary to diabetes or associated with allodynia
Assessments:
• Primary endpoint was pain severity scores recorded using a 0-10 Numerical Rating Scale (NRS-11)
• Secondary endpoints included theNeuropathic Pain Scale (NPS), sleep disturbance NRS-11, Subject Global Impression of Change (SGIC), intoxication NRS-11 and a quality of life EQ-5D 
health questionnaire
• Safety was assessed by monitoring adverse events (AEs) and serial clinical chemistry and vital signs
Study drug: Sativex® (THC:CBD) endocannabinoid system modulator
• Approved in Canada for relief of central neuropathic pain in Multiple 
Sclerosis and cancer pain
• Produced from selected strains of cloned Cannabis sativa plants 
formulated into a spray for oromucosal administration
• Highly standardised formulation: each 100µl spray of Sativex® contains 
2.7 mg delta-9-tetrahydrocannabinol (THC), 2.5 mg cannabidiol (CBD), 
minor cannabinoids (5-6%) and small amounts of other plant extracts such 
as terpenes
• Subjects self-titrated to their optimal dose on the basis of their individual 
efficacy and tolerability response, up to a maximum of 24 sprays/day
Rationale for Treatment:
• Previous clinical trials have shown that Sativex has 
analgesic properties that are effective in relieving 
neuropathic pain
• These studies also suggested that Sativex is well 
tolerated and may also improve sleep and quality of life
• Pain resulting from diabetic neuropathy is often not 
satisfactorily alleviated by existing therapies
NPS and Sleep Quality NRS-11
• Improvement maintained with time and continued to improve up to week 26 (change from 
parent RCT baseline was -21.51 for the NPS and -2.39 for the sleep NRS-11)
SGIC
• 70% of subjects had an improvement in nerve pain
• 8% of subjects had a worsening in nerve pain
Health Outcomes – EQ-5D Questionnaire Score
• Descriptive System Questionnaires (Mobility, Activity, Self care, Pain and Anxiety):
-More subjects improved than worsened in their classification form parent RCT 
baseline
• Weighted Health State Index and Health Status VAS:
- Small improvement in both index and VAS scores, maintained at final visit
Intoxication Scores
• Mean intoxication scores throughout course of study were less than 2 points out of 10
» RESULTS
5. Dosing Data
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